MAI Capital Management’s Sinovac Biotech, Ltd SVA Stock Holding History

MAI Capital Management’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3	Closed	–	–	5012
2026 Q1	$0	Hold	3	–	–	﹤0.01%	5158
2025 Q4	$0	Hold	3	–	–	﹤0.01%	4511
2025 Q3	$0	Hold	3	–	–	﹤0.01%	4174
2025 Q2	$0	Buy	+3	New	–	﹤0.01%	4062

Other funds holding SVA

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Horizon Investments Charlotte, North Carolina $9.13B AUM 34.49% 1-Year Est. Return

MAI Capital Management's SVA Position: Q2 2026 in Review

MAI Capital Management sold out of Sinovac Biotech, Ltd (SVA) in Q2 2026, closing a stake of 3 shares.

MAI Capital Management first reported a position in SVA in Q2 2025 and held it in 4 quarters. The position peaked at $0 in Q1 2026. 28 funds tracked by Wall St. Rank hold SVA as of Q2 2026.

MAI Capital Management reported no remaining Sinovac Biotech, Ltd position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 3 Sinovac Biotech, Ltd shares in Q2 2026.
MAI Capital Management first reported a position in Sinovac Biotech, Ltd in Q2 2025 and held it in 4 quarters.
MAI Capital Management's Sinovac Biotech, Ltd position peaked at $0 in Q1 2026.
28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.